We are at the beginning of a new age in cancer therapy. With
a large and growing number of patents and applications in
this space, we can expect a large amount of patent litigation
in the years to come as companies look to safeguard their
market share. Frances Salisbury and Adam Gregory of
Mewburn Ellis LLP look into the recent FDA approvals, an
important landmark in cellular immunotherapy.
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
The Rise of Cellular Immunotherapy and Global IP Strategies
